The long-term objective of this research program is to develop novel types of phosphoramidate-based anticancer drugs and investigate their mechanisms of action. This drug development program is based upon the design and synthesis of prodrug molecules containing a non-cytotoxic phosphoramidate ester that undergo enzyme-catalyzed activation via cleavage of the ester bond to liberate the highly cytotoxic phosphoramidate anion. A series of bioreductive alkylating agents was developed previously that are highly toxic to tumor cell lines in vitro and have potent antitumor activity in vivo. This strategy will now be extended to the design and synthesis of compounds that can be activated by DT-diaphorase, an enzyme that is overexpressed in a number of human solid tumors, or by beta-lactamase, an enzyme that is used in antibody-directed enzyme prodrug therapy.
Specific aims are to: 1) Develop a 3-dimensional structure-function relationship for human DT-diaphorase to provide a model for the rational design of new drugs; 2) Design, synthesize and evaluate novel phosphoramidate analogs that are activated selectively by the enzyme DT-diaphorase; 3) Design, synthesize and evaluate novel cephalosporin phosphoramidates that are activated selectively by beta-lactamase; 4) Evaluate all new agents for activation and cytotoxicity in vitro, and evaluate selected compounds for antitumor activity in vivo. Purified enzyme preparations will be used to measure the activation of these compounds, and clonogenic assays in B16, MCF-7, HT-29 and BE cell lines will be used to assess cytotoxicity. B16, HT-29 and MX-1 models will be used to evaluate antitumor activity in vivo. The ultimate goal is to exploit the unique properties of phosphoramidate chemistry to develop new drugs with reduced host toxicity and increased efficacy against resistant poorly responsive tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA034619-16
Application #
2683428
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Beisler, John A
Project Start
1982-09-01
Project End
2000-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
16
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Purdue University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
072051394
City
West Lafayette
State
IN
Country
United States
Zip Code
47907
Huang, Rong; Oh, Hyunju; Arrendale, Allison et al. (2013) Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK. Biochem Pharmacol 86:597-611
Marian, Christine; Huang, Rong; Borch, Richard F (2011) Design and synthesis of a potential SH2 domain inhibitor bearing a stereodiversified 1,4-cis-enediol scaffold. Tetrahedron 67:10216-10221
Clark, Michelle K; Scott, Sarah A; Wojtkowiak, Jonathan et al. (2007) Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitors. J Med Chem 50:3274-82
Choi, Jun Young; Borch, Richard F (2007) Highly efficient synthesis of enantiomerically enriched 2-hydroxymethylaziridines by enzymatic desymmetrization. Org Lett 9:215-8
Wu, Weidong; Sigmond, Jennifer; Peters, Godefridus J et al. (2007) Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. J Med Chem 50:3743-6
Boutselis, Irene G; Yu, Xiao; Zhang, Zhong-Yin et al. (2007) Synthesis and cell-based activity of a potent and selective protein tyrosine phosphatase 1B inhibitor prodrug. J Med Chem 50:856-64
Garrido-Hernandez, Hugo; Moon, Kyung D; Geahlen, Robert L et al. (2006) Design and synthesis of phosphotyrosine peptidomimetic prodrugs. J Med Chem 49:3368-76
Wu, Weidong; Borch, Richard F (2006) Synthesis and biological activity of N-2,3-dihydroxypropyl-N-4-chlorobutyl nucleoside phosphoramidate prodrugs. Mol Pharm 3:451-6
Wu, Weidong; Freel Meyers, Caren L; Borch, Richard F (2004) A novel method for the preparation of nucleoside triphosphates from activated nucleoside phosphoramidates. Org Lett 6:2257-60
Tobias, Sandra C; Borch, Richard F (2004) Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm 1:112-6

Showing the most recent 10 out of 32 publications